Literature DB >> 12880963

der(11)t(11;17): a distinct cytogenetic pathway of advanced stage neuroblastoma (NBL) - detected by spectral karyotyping (SKY).

Batia Stark1, Marta Jeison, Leticia Glaser-Gabay, Irit Bar-Am, Jacques Mardoukh, Shifra Ash, Dina Atias, Jerry Stein, Rina Zaizov, Isaac Yaniv.   

Abstract

Conventional cytogenetic, molecular cytogenic and genetic methods disclosed a broad spectrum of genetic abnormalities leading to gain and loss of chromosomal segments in advanced stage neuroblastoma (NBL). Specific correlation between the genetic findings could delineate distinct genetic pathways, of which the biology and prognostic significance is as yet undetermined. Using spectral karyotyping (SKY) and fluorescence in situ hybridization (FISH) on metaphases from 16 patients with advanced stage NBL, it was possible to explore the whole spectrum of rearrangement within complex karyotypes and to detect hidden recurrent translocations. All translocations were unbalanced. The most prevalent recurrent unbalanced translocations resulted in 17q gain in 12 patients (75%), 11q loss in nine patients (56%), and 1p deletion/imbalance in eight patients (50%). The most frequent recurrent translocation was der(11)t(11;17) in six patients. Three cytogenetic pathways could be delineated. The first, with six patients, was characterized by the unbalanced translocation der(11)t(11;17), detected only by SKY, resulting in the concomitant 17q gain and 11q loss. No MYCN amplification or 1p deletion (except one patient with 1p imbalance) were found, while 3p deletion, and complex karyotypes were common. The second subgroup, with four patients, had 17q gain and 1p deletion, and in two patients 11q loss, that was apparent only by FISH. 1p deletion occurred through der(1)t(1;17) or del(1p). The third subgroup of four patients was characterized by MYCN amplification with 17q gain and 1p deletion, very rarely with 11q loss (one patient) through a translocation with a non-17q partner. The SKY subclassifications were in accordance with the findings reported by molecular genetic techniques, and may indicate that distinct oncogenes and suppressor genes are involved in the der(11)t(11;17) pathway of advanced stage NBL.

Entities:  

Mesh:

Year:  2003        PMID: 12880963     DOI: 10.1016/s0304-3835(03)00083-1

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

2.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

3.  Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma.

Authors:  Patrick G Buckley; Leah Alcock; Kenneth Bryan; Isabella Bray; Johannes H Schulte; Alexander Schramm; Angelika Eggert; Pieter Mestdagh; Katleen De Preter; Jo Vandesompele; Frank Speleman; Raymond L Stallings
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

4.  Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations.

Authors:  Samuel W Brady; Yanling Liu; Xiaotu Ma; Alexander M Gout; Kohei Hagiwara; Xin Zhou; Jian Wang; Michael Macias; Xiaolong Chen; John Easton; Heather L Mulder; Michael Rusch; Lu Wang; Joy Nakitandwe; Shaohua Lei; Eric M Davis; Arlene Naranjo; Cheng Cheng; John M Maris; James R Downing; Nai-Kong V Cheung; Michael D Hogarty; Michael A Dyer; Jinghui Zhang
Journal:  Nat Commun       Date:  2020-10-14       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.